Lumos Pharma, Inc. (NASDAQ:LUMO) Short Interest Down 39.3% in November

Lumos Pharma, Inc. (NASDAQ:LUMO) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 54,300 shares, a decrease of 39.3% from the November 15th total of 89,500 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily volume of 83,800 shares, the days-to-cover ratio is presently 0.6 days.

Analysts Set New Price Targets

LUMO has been the topic of several research analyst reports. HC Wainwright reissued a “neutral” rating and set a $4.25 target price on shares of Lumos Pharma in a research note on Friday, November 8th. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a research note on Tuesday, September 24th.

Lumos Pharma Stock Performance

Shares of Lumos Pharma stock remained flat at $4.34 during trading on Thursday. 481,687 shares of the stock traded hands, compared to its average volume of 57,302. The stock has a market capitalization of $37.54 million, a price-to-earnings ratio of -1.01 and a beta of 0.74. Lumos Pharma has a 52-week low of $1.37 and a 52-week high of $4.58. The company’s 50 day moving average price is $4.20 and its 200-day moving average price is $3.21.

Institutional Trading of Lumos Pharma

A hedge fund recently raised its stake in Lumos Pharma stock. Private Advisor Group LLC grew its stake in shares of Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 744,513 shares of the company’s stock after buying an additional 714,500 shares during the quarter. Private Advisor Group LLC owned 9.17% of Lumos Pharma worth $2,881,000 at the end of the most recent quarter. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.